Drug Trial Radar · NCT02386800
CINC424A2X01B Rollover Protocol
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
279
Actual
Start
Mar 5, 2015
Primary completion
Apr 5, 2032
Study completion Apr 5, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Conditions
- Primary Myelofibrosis
- Polycythemia Vera
- Graft Versus Host Disease
- Acute Myeloid Leukemia
- Thalassemia
Interventions
ruxolitinibDrug
ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
panobinostatDrug
panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of AEs and SAEsTime frame: 12 years
Locations
97 sites in 25 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
St Leonards, Australia
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Novartis Investigative Site
Bedford Park, South Australia, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Franston, Victoria, Australia
Novartis Investigative Site
Perth, Western Australia, Australia
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Santiago, RM, Chile
Novartis Investigative Site
Viña del Mar, Valparaiso, Chile
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Kaposvár, Hungary
Novartis Investigative Site
Kecskemét, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Szombathely, Hungary
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site
Pune, Maharashtra, India
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.